CD8+ T-cell receptor recognizing SARS-CoV-2 Spike protein-derived peptides (SARS-CoV-2 Spike-specific TCR) (SARS-CoV-2 Spike-specific TCR)

CD8+ T-cell receptors (TCRs) recognizing SARS-CoV-2 S-2P-derived peptides are critical components of the adaptive immune system's response to COVID-19 (Shomuradova et al., 2020, Immunity). These receptors are expressed on the surface of cytotoxic T cells and specifically bind to viral epitopes presented by Major Histocompatibility Complex (MHC) Class I molecules. The S-2P designation refers to the stabilized prefusion Spike protein used in major mRNA and viral vector vaccines, which contains two proline substitutions (K986P and V987P) to maintain structural integrity and enhance immunogenicity (Wrapp et al., 2020, Science). Upon recognition of these specific peptides, CD8+ T cells are activated to proliferate, secrete pro-inflammatory cytokines like interferon-gamma, and directly eliminate virus-infected cells (Sahin et al., 2020, Nature). In the context of drug development, these TCRs are the primary targets of vaccine-induced immunity and are being explored for adoptive T-cell therapies. Understanding the diversity and binding affinity of these receptors is essential for evaluating vaccine efficacy against emerging variants. Therapeutic challenges include potential cross-reactivity with self-antigens and the risk of cytokine release syndrome in engineered T-cell applications. Monitoring these TCRs through biomarkers like MHC-peptide multimers allows researchers to track the longevity and breadth of the cellular immune response.

Other names

SARS-CoV-2 Spike-specific CD8+ T-cell receptorSpike-reactive TCRS-2P-specific TCRSARS-CoV-2 S-specific CD8+ TCRSARS-CoV-2 S-2P-specific CD8+ TCR

Activation of cytotoxic T-cell responses through the recognition of viral epitopes presented by MHC Class I molecules, leading to the destruction of infected cells and the release of pro-inflammatory cytokines.